The purpose of this study is to compare the effects of varying dosage of coenzyme Q10
(CoQ10) versus a placebo in the treatment of Parkinson's disease (PD) in patients with
early, untreated PD.
Four groups of 20 subjects/group of subjects will be randomly assigned to receive CoQ10 (at
doses of 300, 600 or 1200 mg/day) or matching placebo. A subject must have early PD that
does not require treatment. A subject will be evaluated at a Screening Visit, a Baseline
Visit (after which the subject begins to take the study drug) and visits at 1, 4, 8, 12, and
16 months after the baseline visit. The subject will be followed until she/he needs
treatment with levodopa or for a maximum of 16 months. Because CoQ10 is a component of the
mitochondria (the part of a cell that makes energy), blood samples will be taken at the
baseline visit and the last visit to study mitochondrial function.
- The subjects must have the three cardinal features of PD: slowness of movement,
resting tremor and rigidity. The signs of PD must be greater on one side.
- Disorders that mimic PD.
- Other serious medical problems.